Selective JAK1 inhibitors and the therapeutic applications thereof: a patent review (2016-2023) [0.03%]
选择性JAK1抑制剂及其治疗应用的专利回顾（2016-2023）
Yuhui Gao,Li Lan,Cheng Wang et al.
Yuhui Gao et al.
Introduction: The family of Janus kinases (JAKs) consists of four intracellular non-receptor tyrosine kinases: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Among these four subtypes, JAK1 is the only isoform that can f...
A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present) [0.03%]
2019年至今针对EGFR外显子20插入突变的小分子抑制剂专利分析
Wenjian Zhu,Junping Pei,Xiaoyun Lu
Wenjian Zhu
Introduction: Mutations in epidermal growth factor receptor (EGFR) kinase domain consistently activate downstream signaling pathways, such as the PI3K/AKT/mTOR and RAS/RAF/MEK, thereby promoting tumor growth. Although the...
A patent review of mitogen-activated protein kinase-interacting kinases (MNKs) modulators (2019-present) [0.03%]
2019年以来MAP激酶相互作用激酶(MNKs)调节剂专利分析
Qiang Li,Xiang Chen,Mingzhi Su et al.
Qiang Li et al.
Introduction: The mitogen-activated protein kinase interacting kinases (MNKs) modulate protein translation through the phosphorylation of eukaryotic initiation factor 4E (eIF4E) at serine 209, which is crucial for tumorig...
Jesse A Coker,Shaun R Stauffer
Jesse A Coker
Introduction: WDR5 is an epigenetic scaffolding protein that has attracted significant interest as an anti-cancer drug target, especially in MLL-rearranged leukemias. The most druggable 'WIN-site' on WDR5, which tethers W...
Riccardo Fusco,Zeinab Saedi,Imma Capriello et al.
Riccardo Fusco et al.
Introduction: The E3 ubiquitin ligase Cbl-b is a novel target in immune-oncology, with critical roles in regulating T-cell activation and signaling pathways. By facilitating the ubiquitination and degradation of key signa...
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017-present) [0.03%]
磷二酯酶2(PDE2)抑制剂专利回顾(2017-至今)
Bei Zhang,Mei-Yan Jiang,Wei-Hao Luo et al.
Bei Zhang et al.
Introduction: PDE2 is a dual-specific enzyme that hydrolyzes two intracellular substrates, cAMP and cGMP. PDE2 is mainly distributed in the brain, which indicates that PDE2 can serve as a potential target for central nerv...
Özlen Güzel-Akdemir,Atilla Akdemir
Özlen Güzel-Akdemir
Introduction: Helicobacter pylori infects almost half of the World population. Although many infected people are symptom free, the microorganism can still cause a variety of gastrointestinal disorders and gastric adenocar...
A patent review of UNC-51-like kinase 1/2 inhibitors (2019-present) [0.03%]
2019年以来UNC-51样蛋白激酶1/2抑制剂专利分析进展
Zhiqi Zhang,Dejuan Sun,Yueying Yang et al.
Zhiqi Zhang et al.
Introduction: UNC-51-like kinase 1/2 (ULK1/2) are serine/threonine kinases that play a crucial role in autophagy activation and maintaining cellular homeostasis. Given their broad physiological relevance, ULK1/2 are candi...
Jamshed Iqbal,Sehrish Bano,Imtiaz Ali Khan et al.
Jamshed Iqbal et al.
Introduction: The main enzymes that hydrolyzes nucleotides at the cell surface are nucleoside triphosphate diphosphohydrolases (NTPDases), ecto-nucleotide pyrophosphatases/phosphodiesterases (ENPPs), alkaline phosphatases...
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615 [0.03%]
用于多发性骨髓瘤的三特异性抗CD3 / BCMA / CD38抗体：对US20240132615专利的评估
Cindy Bandala,Donaciano Flores-Robles,Pavel Sierra-Martínez et al.
Cindy Bandala et al.
Introduction: CD38 and BCMA are proteins expressed at high levels in multiple myeloma cells, so they are targets for the development of mono- or multispecific antibodies. ...